Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SCN1A | P35498 | 2/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7698688 | 0.98 | HDAC3 (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL7701328 | 0.92 | TDP1 (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL7703078 | 0.84 | POLB (0.48) | GAALMNASMN1; SMN2SCN2AMEN1 | |
| SCHEMBL9837613 | 0.81 | HDAC3 (0.53) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL9846249 | 0.80 | HDAC3 (0.54) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL9361598 | 0.79 | HDAC3 (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL7702154 | 0.79 | GAA (0.41) | GAALMNASMN1; SMN2MAPTKMT2A | |
| SCHEMBL9559096 | 0.78 | LMNA (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL9328109 | 0.76 | VCAM1 (0.57) | GAAMAPTALOX15ALDH1A1TDP1 | |
| SCHEMBL8702044 | 0.75 | ALOX15 (0.59) | GAALMNASMN1; SMN2MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3914604-B1 | COMPOSITIONS COMPRISING CENSAVUDINE OR ELVUCITABINE FOR TREATING AGE-ASSOCIATED INFLAMMATION AND DISORDERS | UNIV BROWN (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20260021101-A1 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING OR REVERSING AGE-ASSOCIATED INFLAMMATION AND DISORDERS | BROWN UNIVERSITY (US) | 2026-01-22 | — | — | US | disclosed |
| US-12246022-B2 | Compositions and methods for treating, preventing or reversing age associated inflammation and disorders | BROWN UNIVERSITY (US) | 2025-03-11 | — | — | US | disclosed |
| US-20240342168-A1 | SMALL MOLECULE INHIBITORS FOR ANTI-CANCER COMBINATION THERAPY | UNIVERSITY OF CAPE TOWN (ZA) | 2024-10-17 | — | — | US | disclosed |
| US-20240082252-A1 | COMPOSITIONS AND METHODS RELATING TO CANCER | THE PENN STATE RESEARCH FOUNDATION | 2024-03-14 | — | — | US | disclosed |
| US-11793814-B2 | Compositions and methods for treating, preventing or reversing age associated inflammation and disorders | BROWN UNIVERSITY (US) | 2023-10-24 | — | — | US | disclosed |
| WO-2023012501-A1 | SMALL MOLECULE INHIBITORS FOR ANTI-CANCER COMBINATION THERAPY | UNIVERSITY OF CAPE TOWN (ZA) | 2023-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12246022-B2 | Compositions and methods for treating, preventing or reversing age associated inflammation and disorders | SERPINB1, MMP8, TERT | HDAC3 1193/4885HDAC4 840/4885HDAC1 926/4885 |
| US-20240082252-A1 | COMPOSITIONS AND METHODS RELATING TO CANCER | WEE1, WEE2, CHEK2 | HDAC3 892/4885HDAC4 700/4885HDAC1 441/4885 |
| US-20240342168-A1 | SMALL MOLECULE INHIBITORS FOR ANTI-CANCER COMBINATION THERAPY | KPNB1, KPNA2, KPNA1 | HDAC3 1399/4885HDAC4 1305/4885HDAC1 543/4885 |
| US-20260021101-A1 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING OR REVERSING AGE-ASSOCIATED INFLAMMATION AND DISORDERS | TPMT, HPRT1, APRT | HDAC3 3420/4885HDAC4 1478/4885HDAC1 1949/4885 |
| US-11793814-B2 | Compositions and methods for treating, preventing or reversing age associated inflammation and disorders | SERPINB1, MMP8, TERT | HDAC3 1193/4885HDAC4 840/4885HDAC1 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.